[
    [
        {
            "time": "2018-01-02",
            "original_text": "This Biotech Stock Just Flew To A Record After Topping Pfizer In A Study",
            "features": {
                "keywords": [
                    "biotech",
                    "record",
                    "topping",
                    "Pfizer",
                    "study"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-03-15",
            "original_text": "Here's Why Ascendis Pharma Is Rocketing Higher Today",
            "features": {
                "keywords": [
                    "Ascendis",
                    "Pharma",
                    "rocketing",
                    "higher"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 2,
                "Entity_Density": 6,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-10",
            "original_text": "Can This Biotech Puppy Run With the Big Dogs?",
            "features": {
                "keywords": [
                    "biotech",
                    "puppy",
                    "big dogs"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 5,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-05-20",
            "original_text": "AbbVie Gets CHMP Nod for Psoriasis Candidate Risankizumab",
            "features": {
                "keywords": [
                    "AbbVie",
                    "CHMP",
                    "nod",
                    "psoriasis",
                    "Risankizumab"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-06-12",
            "original_text": "Pfizer or Mylan: Who Is Expected to Report Faster EPS Growth?",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Mylan",
                    "EPS",
                    "growth"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-07-05",
            "original_text": "Pfizer Inc. -- Moody's assigns A1 rating to Pfizer's notes; stable outlook",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Moody's",
                    "A1",
                    "rating",
                    "stable outlook"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-08-10",
            "original_text": "Pfizer and Mylan: What to Expect from Revenue Growth in 2019",
            "features": {
                "keywords": [
                    "Pfizer",
                    "Mylan",
                    "revenue",
                    "growth",
                    "2019"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-03-05",
            "original_text": "Phibro Animal Health Corporation (PAHC) Ex-Dividend Date Scheduled for March 05, 2019",
            "features": {
                "keywords": [
                    "Phibro",
                    "Animal",
                    "Health",
                    "ex-dividend",
                    "date"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-02-28",
            "original_text": "Why Sangamo Therapeutics Lost 22.9% of Its Value in February",
            "features": {
                "keywords": [
                    "Sangamo",
                    "Therapeutics",
                    "lost",
                    "value"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 7,
                "Duration": 3,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-03-15",
            "original_text": "What Analysts Recommend for Pfizer and Mylan in March",
            "features": {
                "keywords": [
                    "analysts",
                    "recommend",
                    "Pfizer",
                    "Mylan"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-04-20",
            "original_text": "Market Trends Toward New Normal in Pfizer, Hyatt Hotels, Wipro, Garmin, Ameren, and Qorvo â€” Emerging Consolidated Expectations, Analyst Ratings",
            "features": {
                "keywords": [
                    "market",
                    "trends",
                    "normal",
                    "Pfizer",
                    "Hyatt",
                    "Hotels",
                    "Wipro",
                    "Garmin",
                    "Ameren",
                    "Qorvo"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "consumer goods",
                    "technology",
                    "industrials"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-05-10",
            "original_text": "BioXcel Therapeutics Announces Addition of Merck KGaA, Darmstadt, Germany, and Pfizer to Clinical Collaboration with Nektar for Development of Triple-combination Therapy in Pancreatic Cancer",
            "features": {
                "keywords": [
                    "BioXcel",
                    "Therapeutics",
                    "Merck",
                    "KGaA",
                    "Pfizer",
                    "Nektar",
                    "triple-combination",
                    "therapy",
                    "pancreatic",
                    "cancer"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]